International Clinical Trial: Toripalimab Combined with Single-Agent Chemotherapy for Perioperative Treatment of Resectable Stage II-III Driver Gene-Negative Non-Small Cell Lung Cancer (NSCLC): An Open-Label, Randomized, Single-Center, Phase II Study

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122117) titled 'Toripalimab Combined with Single-Agent Chemotherapy for Perioperative Treatment of Resectable Stage II-III Driver Gene-Negative Non-Small Cell Lung Cancer (NSCLC): An Open-Label, Randomized, Single-Center, Phase II Study' on April 9.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital

Condition: Stage ?-? EGFR/ALK Wild-Type NSCLC

Intervention: Toripalimab + Single-Agent Chemotherapy Arm:Patients first received 2 cycles of neoadjuvant therapy as follows: Toripalimab 240 mg IV Q3W

Recruitment Status: Recruiting

Phase: 2

Da...